#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3554	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2634	401.1	0	.	n	.	0	A69G	SNP	69	69	A	553	553	G	510	G,A	326,96	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3554	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2634	401.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1934	1934	T	547	T	470	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3554	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2634	401.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1668	1668	C	544	C,A	457,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5764	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3925	439.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1880	1880	A	504	A,C	405,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5764	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3925	439.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2514	2514	C	601	C	500	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5764	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3925	439.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2588	2588	A	612	A	496	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5764	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3925	439.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3140	3140	C	487	C,A,T	392,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	532	folP	852	852	99.88	folP.l15.c4.ctg.1	1860	85.6	0	.	p	.	0	E151K	NONSYN	451	453	GAA	937	939	AAA	120;120;121	A,C;A;A	93,1;98;97	.	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	532	folP	852	852	99.88	folP.l15.c4.ctg.1	1860	85.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1168	1170	AGC	128;127;127	A;G;C	104;103;104	folP.WHO_G_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1252	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3763	99.6	1	SNP	p	S91F	0	.	.	271	273	TCC	765	767	TCC	91;91;91	T,G;C;C	72,1;69;74	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1252	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3763	99.6	1	SNP	p	D95G	0	.	.	283	285	GAC	777	779	GAC	85;86;87	G;A;C	72;74;72	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1252	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3763	99.6	1	SNP	p	D95N	0	.	.	283	285	GAC	777	779	GAC	85;86;87	G;A;C	72;74;72	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	516	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1792	86.0	1	SNP	p	G45D	0	.	.	133	135	GGC	764	766	GGC	138;139;138	G;G;C	114;114;112	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	252	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1388	54.5	0	.	n	.	0	A197.	DEL	197	197	A	760	760	A	105	A	85	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1238	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3420	108.5	1	SNP	p	D86N	0	.	.	256	258	GAC	817	819	GAC	172;172;174	G;A,C;C	131;123,1;134	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1238	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3420	108.5	1	SNP	p	S87R	0	.	.	259	261	AGT	820	822	AGT	174;175;175	A,C;G,A;T	122,1;127,1;130	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1238	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3420	108.5	1	SNP	p	S87I	0	.	.	259	261	AGT	820	822	AGT	174;175;175	A,C;G,A;T	122,1;127,1;130	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1238	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3420	108.5	1	SNP	p	S87W	0	.	.	259	261	AGT	820	822	AGT	174;175;175	A,C;G,A;T	122,1;127,1;130	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1238	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3420	108.5	1	SNP	p	S88P	0	.	.	262	264	TCC	823	825	TCC	176;178;179	T,C;C;C	130,1;133;137	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1138	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3070	110.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1748	1750	GGC	159;158;158	G;G;C,A,G	127;121;121,1,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	95.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1433	1435	GCA	186;187;187	G;C;A	141;145;140	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	95.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1436	1438	ATC	188;188;188	A;T;C,T	145;146;146,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	95.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1448	1450	GTG	186;186;187	G;T,C;G	144;136,1;140	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	95.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1448	1450	GTG	186;186;187	G;T,C;G	144;136,1;140	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	95.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1952	1954	ACC	88;88;88	A,C;C;C	74,1;75;73	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	95.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2006	2008	GCG	91;91;92	G;C;G	78;69;76	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	95.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2006	2008	GCG	91;91;92	G;C;G	78;69;76	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	95.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2129	2131	GGC	106;105;105	G,C;G;C	88,1;84;85	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	95.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2138	2140	GGC	105;105;105	G;G;C	85;83;82	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	95.8	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2156	2158	CTG	108;108;109	C;T;G	81;80;88	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1364	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3351	121.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1690	1692	CCG	124;124;124	C;C;G	97;101;105	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	638	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2235	85.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	685	685	C	112	C	92	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1106	16.8	0	.	p	.	0	H217N	NONSYN	649	651	CAT	832	834	AAT	18;18;18	A;A;T	14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1106	16.8	0	.	p	.	0	D218N	NONSYN	652	654	GAT	835	837	AAT	18;18;18	A;A;T	14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1106	16.8	0	.	p	.	0	V226A	NONSYN	676	678	GTA	859	861	GCA	18;18;18	G;C;A	14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1106	16.8	0	.	p	.	0	.	MULTIPLE	700	702	ACT	882	884	GTA	18;18;18	G;T;A	14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1106	16.8	0	.	p	.	0	S236N	NONSYN	706	708	AGC	888	890	AAC	18;18;18	A,C;A;C	13,1;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1106	16.8	0	.	p	.	0	.	MULTIPLE	709	711	AAC	892	896	TGGCG	17;17;17;17;17	T;G;G;C;G	13;12;13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1106	16.8	0	.	p	.	0	D238A	NONSYN	712	714	GAT	898	900	GCT	17;17;17	G;C;T	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1106	16.8	0	.	p	.	0	V258L	NONSYN	772	774	GTA	958	960	TTA	15;15;15	T;T;A	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1106	16.8	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1003	1005	CAT	19;19;19	C;A;T	13;11;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1106	16.8	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1006	1008	AGT	19;19;19	A;G;T	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1106	16.8	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1015	1017	TAC	20;20;20	T;A;C	13;13;13	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	768	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2021	111.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	625	627	GAA	131;130;130	G;A;A	102;103;102	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	768	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2021	111.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	913	915	GAT	139;139;139	G;A;T	98;102;103	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	768	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2021	111.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1036	1038	TCA	142;144;144	T,A;C;A,C	119,2;123;121,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	768	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2021	111.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1165	1167	GTC	171;170;170	G,C,T;T;C	137,1,1;137;133	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	768	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2021	111.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1495	1497	GCA	192;192;190	G;C,A;A	155;155,1;153	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	768	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2021	111.6	1	SNP	p	G120K	1	.	.	358	360	AAG	871	873	AAG	142;143;143	A;A;G	104;107;107	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	768	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2021	111.6	1	SNP	p	A121D	1	.	.	361	363	GAC	874	876	GAC	143;142;140	G,A;A;C	105,1;110;107	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	768	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2021	111.6	1	SNP	p	D121N	0	.	.	361	363	GAC	874	876	GAC	143;142;140	G,A;A;C	105,1;110;107	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	2578	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5261	146.7	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2182	2184	AAT	126;127;127	A;A;T,G	107;107;106,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	394	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1384	85.2	1	SNP	p	V57M	1	.	.	169	171	ATG	675	677	ATG	167;167;168	A;T;G	127;132;130	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
